Home > Insider Trading > Filing (0001585283-13-000026)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1369786	Sagent Pharmaceuticals Inc.	SGNT	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1230193	Morgan Stanley Investment Management Inc	522 Fifth Avenue 4Th Floor New York NY 10036		No	No	Yes	No
1230207	Morgan Stanley Aip Gp Lp	100 Front Street Suite 400 West Conshohcoken PA 19428		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2013-10-01	50,000	$20.70	3,819,139	No	4	S	Indirect	See footnote
Common Stock	Acquisiton	2013-10-02	40,020	$20.32	3,779,119	No	4	S	Indirect	See footnote (2) (3)

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote (2) (3)

Footnotes

Represents shares of Common Stock owned by certain funds (each, a "Fund" and collecitively, the "Funds") and certain separately managed accounts managed by the undersigned.
The shares reported are held of record by Stormlaunch & Co., Sailorshell & Co., Stormbay & Co., Stormstar & Co., Weyerhaeuser Company Master Retirement Trust, Sailorpier & Co., Factory Mutual Insurance Company and Nuclear Electric Insurance Limited.
The reported securities are held directly by the Funds and certain separately managed accounts managed by each of the reporting persons. Morgan Stanley Investment Management Inc. ("MSIM") is the investment manager of one or moare of the separately managed accounts and Morgan Stanley AIP GP LP ("AIP") is the investment manager of one or more of the Funds. This form is filed without prejudice to the reporting persons' position that none of the Funds nor any subsidiaries of the reporting persons, nor the reporting persons individually or in aggregate, are required to file beneficial ownership reports under Section 16(a) of the Securities Exchange Act of 1934, and should not be construed or interpreted as a concession or admission that such reports are required.